Griffith & Werner Inc. bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 102,917 shares of the biopharmaceutical company's stock, valued at approximately $2,730,000. Pfizer comprises 1.8% of Griffith & Werner Inc.'s portfolio, making the stock its 20th largest holding.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Rialto Wealth Management LLC acquired a new position in Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the 4th quarter worth about $27,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter worth $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer during the 4th quarter worth about $31,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer in the fourth quarter worth $33,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Trading Down 1.1%
Shares of Pfizer stock traded down $0.27 during trading on Wednesday, reaching $23.35. 13,784,794 shares of the stock were exchanged, compared to its average volume of 40,974,047. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock's fifty day moving average is $23.28 and its 200 day moving average is $25.12. The firm has a market cap of $132.72 billion, a price-to-earnings ratio of 16.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.
Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.82 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.37%. Pfizer's dividend payout ratio is presently 124.64%.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on PFE shares. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and a consensus price target of $29.17.
Read Our Latest Stock Report on PFE
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
